Mifamurtide

Mifamurtide
Clinical data
Trade names	Mepact
License data	EU EMA: by INN;
Pregnancy; category	not investigated;
Routes of; administration	intravenous liposomal infusion over one hour
ATC code	L03AX15 (WHO) ;
Legal status
Legal status	In general: ℞ (Prescription only);
Pharmacokinetic data
Bioavailability	N/A
Elimination half-life	minutes (in plasma); 18 hrs (terminal)
Identifiers
	IUPAC name 2-[(N-{(2R)-[(2-acetamido-2,3-dideoxy-D-glucopyranos-3-yl)oxy]-propanoyl}-L-alanyl-D-isoglutaminyl-L-alanyl)amino]ethyl (2R)-2,3-bis(hexadecanoyloxy)propyl hydrogen phosphate;
CAS Number	83461-56-7 ; 838853-48-8 (mifamurtide sodium · x H2O);
PubChem CID	11672602;
IUPHAR/BPS	8274;
ChemSpider	9847332 ;
UNII	EQD2NNX741;
KEGG	D06619 ;
ChEBI	CHEBI:135906;
ChEMBL	ChEMBL2111100;
Chemical and physical data
Formula	C59H109N6O19P
Molar mass	1237.518 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCCNC(=O)[C@H](C)NC(=O)CC[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1C(O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O)C(N)=O)OC(=O)CCCCCCCCCCCCCCC;
	InChI InChI=1S/C59H109N6O19P/c1-7-9-11-13-15-17-19-21-23-25-27-29-31-33-50(69)79-40-46(83-51(70)34-32-30-28-26-24-22-20-18-16-14-12-10-8-2)41-81-85(77,78)80-38-37-61-56(73)42(3)62-49(68)36-35-47(55(60)72)65-57(74)43(4)63-58(75)44(5)82-54-52(64-45(6)67)59(76)84-48(39-66)53(54)71/h42-44,46-48,52-54,59,66,71,76H,7-41H2,1-6H3,(H2,60,72)(H,61,73)(H,62,68)(H,63,75)(H,64,67)(H,65,74)(H,77,78)/t42-,43-,44+,46+,47+,48+,52+,53+,54+,59?/m0/s1 ; Key:JMUHBNWAORSSBD-WKYWBUFDSA-N ;
	(what is this?) (verify)

Mifamurtide (trade name Mepact, marketed by Takeda) is a drug against osteosarcoma, a kind of bone cancer mainly affecting children and young adults, which is lethal in over half of cases. The drug was approved in Europe in March 2009.